Taiho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2012

Global Markets Direct, May 2012, Pages: 109

Taiho Pharmaceutical Co., Ltd. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Taiho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2012” provides data on the Taiho Pharmaceutical Co., Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Taiho Pharmaceutical Co., Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Taiho Pharmaceutical Co., Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Taiho Pharmaceutical Co., Ltd. - Brief Taiho Pharmaceutical Co., Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Taiho Pharmaceutical Co., Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Taiho Pharmaceutical Co., Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Taiho Pharmaceutical Co., Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Taiho Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Taiho Pharmaceutical Co., Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Taiho Pharmaceutical Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Taiho Pharmaceutical Co., Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Taiho Pharmaceutical Co., Ltd. and identify potential opportunities in those areas.

Keyword

Current R&D Portfolio of Taiho Pharmaceutical Co., Ltd.; Taiho Pharmaceutical Co., Ltd. - Key Therapeutics; Taiho Pharmaceutical Co., Ltd. - Pipeline Overview and Promising Molecules; Taiho Pharmaceutical Co., Ltd. - News; Taiho Pharmaceutical Co., Ltd. - Latest Updates; Taiho Pharmaceutical Co., Ltd. - Pipeline; Taiho Pharmaceutical Co., Ltd. - Discontinued/Dormant Projects

List of Tables
List of Figures
Taiho Pharmaceutical Co., Ltd. Snapshot
Taiho Pharmaceutical Co., Ltd. Overview
Key Information
Key Facts
Taiho Pharmaceutical Co., Ltd. – Research and Development Overview
Key Therapeutic Areas
Taiho Pharmaceutical Co., Ltd. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Taiho Pharmaceutical Co., Ltd. – Pipeline Products Glance
Taiho Pharmaceutical Co., Ltd. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Taiho Pharmaceutical Co., Ltd. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Taiho Pharmaceutical Co., Ltd. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Taiho Pharmaceutical Co., Ltd. – Drug Profiles
ABI-007 + TS-1
Product Description
Mechanism of Action
R&D Progress
Abraxane
Product Description
Mechanism of Action
R&D Progress
ARH-1029
Product Description
Mechanism of Action
R&D Progress
Product Description
Mechanism of Action
R&D Progress
CPT-11 + TS-1
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + TS-1
Product Description
Mechanism of Action
R&D Progress
Mocetinostat
Product Description
Mechanism of Action
R&D Progress
OVF
Product Description
Mechanism of Action
R&D Progress
S-1
Product Description
Mechanism of Action
R&D Progress
S-1 + Cisplatin
Product Description
Mechanism of Action
R&D Progress
S-1 + Irinotecan + Bevacizumab
Product Description
Mechanism of Action
R&D Progress
S-1 + Leucovorin
Product Description
Mechanism of Action
R&D Progress
S-1 + Leucovorin + Oxaliplatin + Bevacizumab
Product Description
Mechanism of Action
R&D Progress
S-1 + Oxaliplatin
Product Description
Mechanism of Action
R&D Progress
S-1 + Oxaliplatin + Bevacizumab
Product Description
Mechanism of Action
R&D Progress
S-1 + Oxaliplatin + Leucovorin
Product Description
Mechanism of Action
R&D Progress
S-1 + Sorafenib
Product Description
Mechanism of Action
R&D Progress
TAC-201
Product Description
Mechanism of Action
R&D Progress
TAS-106
Product Description
Mechanism of Action
R&D Progress
TAS102
Product Description
Mechanism of Action
R&D Progress
TSU-68
Product Description
Mechanism of Action
R&D Progress
TSU-68 + Docetaxel
Product Description
Mechanism of Action
R&D Progress
TSU-68 + S-1 + Oxaliplatin
Product Description
Mechanism of Action
R&D Progress
TSU-68 + TS-1 + CDDP
Product Description
Mechanism of Action
R&D Progress
YP-18
Product Description
Mechanism of Action
R&D Progress
Taiho Pharmaceutical Co., Ltd. – Pipeline Analysis
Taiho Pharmaceutical Co., Ltd. – Pipeline Products by Therapeutic Class
Taiho Pharmaceutical Co., Ltd. – Pipeline Products By Target
Taiho Pharmaceutical Co., Ltd. – Pipeline Products by Route of Administration
Taiho Pharmaceutical Co., Ltd. – Pipeline Products By Mechanism of Action
Taiho Pharmaceutical Co., Ltd. – Recent Pipeline Updates
Taiho Pharmaceutical Co., Ltd. - Dormant Projects
Taiho Pharmaceutical Co., Ltd. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
IPD-1151T
Taiho Pharmaceutical Co., Ltd. – Company Statement
Taiho Pharmaceutical Co., Ltd. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Taiho Pharmaceutical Co., Ltd., Recent Developments
Taiho Pharmaceutical Co., Ltd.- Press Release
Apr 10, 2012: Taiho Pharma Announces Launch Of Teysuno In UK
Apr 03, 2012: Taiho Pharma Receives Marketing Authorization Approval For TS-1 In Hong Kong
Mar 21, 2012: Taiho Pharmaceutical And Nordic Group Launch Teysuno In Sweden, Denmark, Norway And Finland
Mar 21, 2012: Taiho Pharmaceutical Receives Marketing Authorization For TS-1 In Thailand
Financial Deals Landscape
Taiho Pharmaceutical Co., Ltd., Deals Summary
Taiho Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deal Details
Partnerships
Ajinomoto Pharma And Taiho Pharma To Terminate Distribution Agreement For Lentinan I.V. Infusion 1 mg, Ajinomoto
Taiho Pharma Enters Into Development Agreement With Nordic Group For Teysuno
MSD Enters Into Co-Marketing Agreement With Taiho Pharma For Vorinostat
Taiho Pharma Enters Into Agreement With Toray Industries
Taiho Pharma Enters Into Co-Development Agreement With Nippon Shinyaku
Makoto Life Sciences Enters Into Research Collaboration Agreement With Taiho Pharma
Yakult Honsha Enters Into Co-Promotion Agreement With Taiho Pharma
Pharmacopeia Enters Into Co-Development Agreement With Taiho Pharma
Taiho Pharma Enters Into Co-Development Agreement With Ligand Pharma
Licensing Agreements
Taiho Pharma Extends Licensing Agreement With Helsinn Healthcare
Taiho Pharma Enters Into Licensing Agreement With Pharmamar
aRigen Pharma Enters Into Licensing Agreement With Taiho Pharma
Taiho Pharma Signs Licensing Agreement With Sanofi-Aventis
American BioScience Enters Into Licensing Agreement With Taiho Pharma
Merck Enters Into Licensing Agreement With Taiho Pharma
Taiho Pharma Signs Licensing Agreement With Helsinn Healthcare
Acquisition
Toho Pharma Acquires Remaining Stake In Koyo Co
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Taiho Pharmaceutical Co., Ltd., Key Information
Taiho Pharmaceutical Co., Ltd., Key Facts
Taiho Pharmaceutical Co., Ltd. – Pipeline by Indication, 2012
Taiho Pharmaceutical Co., Ltd. – Pipeline by Stage of Development, 2012
Taiho Pharmaceutical Co., Ltd. – Monotherapy Products in Pipeline, 2012
Taiho Pharmaceutical Co., Ltd. – Combination Treatment Modalities in Pipeline, 2012
Taiho Pharmaceutical Co., Ltd. – Filed, 2012
Taiho Pharmaceutical Co., Ltd. – Phase III, 2012
Taiho Pharmaceutical Co., Ltd. – Phase II, 2012
Taiho Pharmaceutical Co., Ltd. – Phase I, 2012
Taiho Pharmaceutical Co., Ltd. – Pre-Clinical, 2012
Taiho Pharmaceutical Co., Ltd. – Pipeline By Therapeutic Class, 2012
Taiho Pharmaceutical Co., Ltd. - Pipeline By Target, 2012
Taiho Pharmaceutical Co., Ltd. – Pipeline By Route of Administration, 2012
Taiho Pharmaceutical Co., Ltd. – Pipeline Products By Mechanism of Action, 2012
Taiho Pharmaceutical Co., Ltd. – Recent Pipeline Updates, 2012
Taiho Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2012
Taiho Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2012
Taiho Pharmaceutical Co., Ltd., Subsidiaries
Taiho Pharmaceutical Co., Ltd., Deals Summary
Ajinomoto Pharma And Taiho Pharma To Terminate Distribution Agreement For Lentinan I.V. Infusion 1 mg, Ajinomoto
Taiho Pharma Enters Into Development Agreement With Nordic Group For Teysuno
MSD Enters Into Co-Marketing Agreement With Taiho Pharma For Vorinostat
Taiho Pharma Enters Into Agreement With Toray Industries
Taiho Pharma Enters Into Co-Development Agreement With Nippon Shinyaku
Makoto Life Sciences Enters Into Research Collaboration Agreement With Taiho Pharma
Yakult Honsha Enters Into Co-Promotion Agreement With Taiho Pharma
Pharmacopeia Enters Into Co-Development Agreement With Taiho Pharma
Taiho Pharma Enters Into Co-Development Agreement With Ligand Pharma
Taiho Pharma Extends Licensing Agreement With Helsinn Healthcare
Taiho Pharma Enters Into Licensing Agreement With Pharmamar
aRigen Pharma Enters Into Licensing Agreement With Taiho Pharma
Taiho Pharma Signs Licensing Agreement With Sanofi-Aventis
American BioScience Enters Into Licensing Agreement With Taiho Pharma
Merck Enters Into Licensing Agreement With Taiho Pharma
Taiho Pharma Signs Licensing Agreement With Helsinn Healthcare
Toho Pharma Acquires Remaining Stake In Koyo Co

List of Figures
Taiho Pharmaceutical Co., Ltd. – Pipeline by Indication, 2012
Taiho Pharmaceutical Co., Ltd. – Pipeline by Stage of Development, 2012
Taiho Pharmaceutical Co., Ltd. – Monotherapy Products in Pipeline, 2012
Taiho Pharmaceutical Co., Ltd. – Combination Treatment Modalities in Pipeline, 2012
Taiho Pharmaceutical Co., Ltd. – Pipeline By Therapeutic Class, 2012
Taiho Pharmaceutical Co., Ltd. - Pipeline By Target, 2012
Taiho Pharmaceutical Co., Ltd. – Pipeline By Route of Administration, 2012
Taiho Pharmaceutical Co., Ltd. - Pipeline Products By Mechanism of Action, 2012

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• eBay - Strong Execution
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Amazon - Point of Realization in 2013?
• SunGard - Profile - US
• Scientific Games Corporation - Company Analysis
• Ixia - Company Analysis
• US - Accenture - Company Profile
• US - TCS - Company Profile